This Is Why with Dr. Busti

Anthony Busti, MD, PharmD, MSc, FNLA, FAHA

This Is Why exists to help medical professionals understand the why behind the decisions they make every day in patient care. Our approach is about integrating evidence, clinical relevance and real-world application so that what your learn connects directly with the patients you serve. 

  1. JAN 27

    LAMA (Long-Acting Muscarinic Antagonists) Bronchodilators for COPD

    In this lecture from This is Why, Dr. Busti will explain the COPD maintenance inhalers you’ll actually see in practice. In this pharmacology review, we break down LAMA (long-acting muscarinic antagonist) bronchodilators—one of the most important bronchodilator classes for COPD treatment—so you can confidently understand the drugs, the mechanism, and the real-world clinical use. You’ll learn how to: What LAMA / antimuscarinic bronchodilators are and how they workWhere LAMA inhalers fit in COPD therapy and long-term symptom controlKey differences and practical pearls for common COPD inhalersHigh-yield side effects, contraindications, and patient counseling pointsHow to recognize and avoid common med errors and confusion with inhaler names/classesDrugs covered: Tiotropium (Spiriva)Umeclidinium (Incruse Ellipta)Aclidinium (Tudorza Pressair)Glycopyrrolate (COPD maintenance formulations)The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/lama-bronchodilators-copd-tiopotropium-umeclidinium-pharmacology Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    26 min

  2. JAN 27

    SAMA (Short-Acting Muscarinic Antagonists) Bronchodilator Pharmacology

    Short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care. In this lecture from This is Why, Dr. Busti will learn about short-acting muscarinic antagonists (SAMAs) are a core bronchodilator drug class you’ll see constantly in COPD care—and on exams like the NCLEX. In this lecture, you’ll learn exactly how SAMAs work, when to use them, and what safety pearls can help you avoid common clinical pitfalls in COPD. You’ll learn how to: Mechanism of action: muscarinic (M3) blockade → decreased bronchoconstrictionKey drug: ipratropium (Atrovent)Common combinations: ipratropium/albuterol (DuoNeb, Combivent)Clinical uses: COPD maintenance/symptom relief, COPD exacerbation support, select asthma situations (often as add-on therapy in acute care)Routes & devices: MDI vs nebulized treatments, dosing frequency, and practical inhaler/neb pearlsAdverse effects & warnings: dry mouth, cough, urinary retention (BPH), blurry vision/precipitating angle-closure symptoms if sprayed into eyes, and other anticholinergic considerationsHigh-yield comparisons: SAMA vs LAMA (where tiotropium and other long-acting agents fit)The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sama-short-acting-muscarinic-antagonist-ipratropium-bronchodilator Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    24 min

  3. JAN 27

    GLP-1 Receptor Agonists (eg, Semaglutide) Diabetes Pharmacology Review

    Understand the GLP-1 receptor agonists—and why agents like semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide, dulaglutide, and exenatide have become one of the most talked-about type 2 diabetes medications in modern practice. In this lecture from This is Why, Dr. Busti will break GLP-1s down in a clear, clinically relevant way so you can confidently explain how they work, when to use them, and what to watch for clinically when managing patients with type 2 diabetes and/or obesity. You’ll learn how to: - Mechanism of action: incretin mimetic effects (GLP-1) and what that means for glucose control - Therapeutic use: where GLP-1 agonists fit in type 2 diabetes (T2DM) treatment strategies - Key agents: semaglutide, plus comparisons to liraglutide, dulaglutide, and exenatide - Benefits & counseling pearls: weight effects, dosing basics, and practical patient education - Adverse effects & precautions: the high-yield safety points clinicians get tested on (and seen in clinical practice) The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/glp-1-receptor-agonists-semaglutide-dulaglutide-liraglutide-diabetes-pharmacology-review Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #glp1receptoragonist #semaglutide #type2diabetes #diabetesmedications #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    46 min

  4. JAN 27

    Insulin Types: Rapid, NPH, Basal for Diabetes - Pharmacology Review

    Insulin doesn’t have to be confusing when learning how to treat Type 1 and Type 2 diabetes mellitus. In this lecture from This is Why, Dr. Busti will explain how to quickly recognize insulin types, predict onset/peak/duration, and apply basal–bolus dosing concepts to real-world Type 1 and Type 2 diabetes care. You’ll learn how to: - How to identify rapid-, short-, intermediate-, and long-acting insulin for Diabetes - The difference between basal insulin vs bolus (mealtime) insulin - How basal–bolus regimens work (plus common pitfalls) - Practical tips for insulin administration, timing with meals, and avoiding errors - High-yield clinical points you’re likely to see in courses and on exams Insulins covered (for memorization + exam success): - Rapid-acting: insulin lispro, aspart, glulisine - Short-acting: regular insulin - Intermediate-acting: NPH insulin - Long-acting / basal: insulin glargine, detemir, degludec - Premixed options: 70/30 mixes (NPH/regular and related premixed products) The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/insulin-types-diabetes-pharmacology-review Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #insulin #diabetes #insulintypes #diabetespharmacology #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    1h 1m

  5. JAN 27

    LABA (Long-Acting Beta Agonists) Bronchodilators for Asthma & COPD

    In this lecture from This is Why, Dr. Busti will explain how Long-Acting Beta Agonists (LABAs) work, where they fit in therapy for the management of asthma and COPD. You’ll learn how to: - Mechanism of action: beta-2 receptor activation → bronchodilation (airway smooth muscle relaxation) - Clinical use: LABAs in COPD maintenance vs asthma (must be combined with ICS) - Onset/duration differences and practical inhaler considerations - Adverse effects & warnings: tachycardia, tremor, hypokalemia, paradoxical bronchospasm, and key safety concepts - Therapeutic combos: ICS/LABA combination inhalers and where they fit (including common guideline concepts) LABA drugs discussed for SEO/review: - Salmeterol - Formoterol - Vilanterol - Olodaterol - Indacaterol The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/laba-long-acting-beta-agonists-asthma-copd-bronchodilators-pharmacology Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #LABA #LongActingBetaAgonist #Asthma #Bronchodilators #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    36 min

  6. JAN 27

    Meglitinides (Nateglinide & Repaglinide): Diabetes Pharmacology Review

    Meglitinides (Nateglinide & Repaglinide) can feel like the “forgotten” oral diabetes drugs—but they show up on exams, in real-world medication histories, and in questions about postprandial glucose control and hypoglycemia and weight gain risk. In this lecture from This is Why, Dr. Busti will explain the meglitinides in a clear, clinically relevant way so you can recognize them quickly and use the concepts confidently in the context of Type 2 diabetes (T2DM). You’ll learn how to: - Meglitinides overview: where they fit in type 2 diabetes (T2DM) therapy - Drug names you must know: repaglinide and nateglinide - Mechanism of action: how these insulin secretagogues stimulate insulin release (the KATP channel connection) - Onset/duration & dosing concept: why they’re considered short-acting / prandial glucose agents - Therapeutic application: targeting postprandial hyperglycemia and when they may (or may not) be chosen - Adverse effects & safety: hypoglycemia, weight considerations, and key patient counseling points The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/meglitinides-repaglinide-nateglinide-diabetes-pharmacology-review Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #meglitinides #repaglinide #nateglinide #type2diabetes #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    13 min

  7. JAN 27

    SABA (Short-Acting Beta Agonists) Bronchodilators for Asthma & COPD

    In this lecture from This is Why, Dr. Busti will break down SABA (Short-Acting Beta Agonist) bronchodilators, like albuterol, for the acute management of asthma symptoms and COPD flare-ups. You’ll learn how to: - What SABAs are and when they’re used (rescue vs controller) - Beta-2 agonist mechanism of action (bronchodilation and smooth muscle effects) - How fast albuterol works, typical duration, and why it’s “short-acting” - Core therapeutic uses in asthma and COPD - How SABAs fit into treatment plans (including “as needed” use) - Common adverse effects: tachycardia, tremor, palpitations, and more - Key patient counseling: inhaler technique and when to seek urgent care Drugs discussed: - Albuterol (rescue inhaler; MDI and nebulizer) - Levalbuterol (alternative SABA) The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/saba-short-acting-beta-agonists-albuterol-rescue-inhaler-asthma-copd Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #SABA #albuterol #asthma #COPD #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    39 min

  8. JAN 27

    SGLT2 Inhibitors (eg, Empagliflozin) for Diabetes: Pharmacology Review

    SGLT2 inhibitors (bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C. You’ll learn how to: - Mechanism of action (MOA): how SGLT2 blockade drives glucosuria, modest A1c reduction, weight loss, and BP lowering - Clinical use: where SGLT2 inhibitors fit for type 2 diabetes, plus major outcomes in heart failure and chronic kidney disease (CKD) (cardiorenal protection is a key reason they’re prioritized in modern guidelines) - Key drugs (for exams + real-world practice): Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin (Steglatro), and Bexagliflozin (Brenzavvy) - Adverse effects & safety pearls: genital mycotic infections, volume depletion/hypotension, AKI considerations, and the “don’t-miss” rare events like euglycemic DKA (plus how to recognize it) The goal = make medical education easy and clinically relevant. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-diabetes-pharmacology-review Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #sglt2inhibitors #empagliflozin #type2diabetes #diabetespharmacology #busti Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

    35 min
See All (75)

Ratings & Reviews

5
out of 5
3 Ratings

About

This Is Why exists to help medical professionals understand the why behind the decisions they make every day in patient care. Our approach is about integrating evidence, clinical relevance and real-world application so that what your learn connects directly with the patients you serve. 

Information

  • Creator
    Anthony Busti, MD, PharmD, MSc, FNLA, FAHA
  • Years Active
    2025 - 2026
  • Episodes
    75
  • Rating
    Clean
  • Copyright
    © 2026 This Is Why with Dr. Busti
  • Show Website
    This Is Why with Dr. Busti